

Longevity 5:

Fifth International Longevity Risk and Capital Markets Solutions Conference
New York City

POPULATION BASIS RISK AND HEDGE EFFECTIVENESS

Hedging Longevity Risk

Guy Coughlan, Managing Director
Pension Advisory Group

September 25, 2009

This presentation was prepared exclusively for the benefit and internal use of the J.P. Morgan client to whom it is directly addressed and delivered (including such client's subsidiaries, the "Company") in order to assist the Company in evaluating, on a preliminary basis, the feasibility of a possible transaction or transactions and does not carry any right of publication or disclosure, in whole or in part, to any other party. This presentation is for discussion purposes only and is incomplete without reference to, and should be viewed solely in conjunction with, the oral briefing provided by J.P. Morgan. Neither this presentation nor any of its contents may be disclosed or used for any other purpose without the prior written consent of J.P. Morgan.

The information in this presentation is based upon any management forecasts supplied to us and reflects prevailing conditions and our views as of this date, all of which are accordingly subject to change. J.P. Morgan's opinions and estimates constitute J.P. Morgan's judgment and should be regarded as indicative, preliminary and for illustrative purposes only. In preparing this presentation, we have relied upon and assumed, without independent verification, the accuracy and completeness of all information available from public sources or which was provided to us by or on behalf of the Company or which was otherwise reviewed by us. In addition, our analyses are not and do not purport to be appraisals of the assets, stock, or business of the Company or any other entity. J.P. Morgan makes no representations as to the actual value which may be received in connection with a transaction nor the legal, tax or accounting effects of consummating a transaction. Unless expressly contemplated hereby, the information in this presentation does not take into account the effects of a possible transaction or transactions involving an actual or potential change of control, which may have significant valuation and other effects.

Notwithstanding anything herein to the contrary, the Company and each of its employees, representatives or other agents may disclose to any and all persons, without limitation of any kind, the U.S. federal and state income tax treatment and the U.S. federal and state income tax structure of the transactions contemplated hereby and all materials of any kind (including opinions or other tax analyses) that are provided to the Company relating to such tax treatment and tax structure insofar as such treatment and/or structure relates to a U.S. federal or state income tax strategy provided to the Company by J.P. Morgan.

J.P. Morgan's policies prohibit employees from offering, directly or indirectly, a favorable research rating or specific price target, or offering to change a rating or price target, to a subject company as consideration or inducement for the receipt of business or for compensation. J.P. Morgan also prohibits its research analysts from being compensated for involvement in investment banking transactions except to the extent that such participation is intended to benefit investors.

IRS Circular 230 Disclosure: JPMorgan Chase & Co. and its affiliates do not provide tax advice. Accordingly, any discussion of U.S. tax matters included herein (including any attachments) is not intended or written to be used, and cannot be used, in connection with the promotion, marketing or recommendation by anyone not affiliated with JPMorgan Chase & Co. of any of the matters addressed herein or for the purpose of avoiding U.S. tax-related penalties.

J.P. Morgan is a marketing name for investment banking businesses of JPMorgan Chase & Co. and its subsidiaries worldwide. Securities, syndicated loan arranging, financial advisory and other investment banking activities are performed by a combination of J.P. Morgan Securities Inc., J.P. Morgan plc, J.P. Morgan Securities Ltd. and the appropriately licensed subsidiaries of JPMorgan Chase & Co. in Asia-Pacific, and lending, derivatives and other commercial banking activities are performed by JPMorgan Chase Bank, N.A. J.P. Morgan deal team members may be employees of any of the foregoing entities.

This presentation does not constitute a commitment by any J.P. Morgan entity to underwrite, subscribe for or place any securities or to extend or arrange credit or to provide any other services.

"Buy an annuity cheap, and make your life interesting to yourself and everybody else that watches the speculation."

- Charles Dickens (1812 - 1870)

Overview

■ Hedging longevity risk with index-based hedges

- Can be beneficial because
 - The only practical alternative for deferred pensions/annuities
 - Some pension plans are too large to fully hedge any other way
 - Cost and liquidity
- Basis risk must be measured

■ Framework for basis risk analysis

- Focus on Data and Context

■ Empirical analysis of UK and US case studies

- Widely available data
- Evidence of stable relationships between them
- Risk reduction using national population longevity index-based hedges can be significant if hedge optimally calibrated

Agenda

	Page
Framework for longevity basis risk	2
Example from the UK	8
Example from the US	21
Drawing conclusions	31

What is basis risk?

- **Basis risk** refers to the mismatch associated with a hedging relationship
 - Present in most financial hedges
 - Differences between underlying exposure and hedging instrument
 - Leads to residual risks because the hedge is imperfect


- **Longevity basis risk** refers to mismatch in demographics between the beneficiaries of a pension plan or annuity portfolio and the population associated with the longevity hedging instrument
 - Gender basis
 - Age basis
 - Socioeconomic basis
 - Geography basis

Framework for analyzing basis risk and hedge effectiveness

- Framework must be aligned to the objective of longevity hedging
 - Focus on the implications for hedge effectiveness
- Key elements:
 1. Data:
 - Metric
 - Time horizon
 - Analytical method
 2. Context
- Framework must recognize that data is likely to be insufficient
 - Most pension plans and annuity portfolios don't have enough historical data to draw rigorous statistical conclusions
 - Careful analysis using available data but also taking account of demographic, social and economic context

Conclusions based on judgment not statistical proofs

Metrics for analyzing basis risk

1. Mortality rates
 2. Mortality improvements
 3. Survival rates
 4. Life expectancy
 5. Liability cash flows
 6. Liability values
- ← *Underlying observable data*
- Derived data*
- 

- Simple comparison of mortality rates can be misleading
 - Mortality rates do not directly relate to hedge effectiveness
 - Annual mortality rates contain a lot of “noise”

Time horizon for basis risk analysis should be long

- Longevity risk is a slowly-building cumulative trend risk that should be evaluated over long horizons
 - Metrics should be compared over multi-year horizons
 - This better reflects the nature of the risk
 - Helps reduce the impact of noise that can give misleading results
- But long horizons mean fewer independent observations available from historical data.

Selecting an appropriate time horizon involves a trade-off

Analytical methods

- Analytical approaches to explore relationship between populations:

- **Correlation**

- E.g. correlation in improvements in mortality rates

- **Regression**

- E.g., regression of life expectancies through time

- **Graphical assessment**

- E.g., stability of ratio of survival rates through time

- **Risk reduction**

- E.g., reduction in volatility of liability value after hedging

- Techniques to reduce noise:

- Graduation of mortality rates

- Age bucketing

- Long-term horizon

Agenda


	Page
Framework for longevity basis risk	2
Example from the UK	8
Example from the US	21
Drawing conclusions	31

UK males who own life assurance: “CMI Assured Lives”

- Assured population is an affluent subset of the national population
 - Data collected by the CMI (Continuous Mortality Investigation)
 - Contributors are UK Life offices

- Characterized by:
 - Lower mortality rates
 - Higher mortality improvements
 - Higher life expectancy
 - Fewer lives at high ages
 - Number of lives variable
 - Contributors vary

Male assured lives (CMI)



Source: Longevity (www.longevity.co.uk)

At face value basis risk relative to national population is “high”

Setting the context

■ CMI assured lives:


- A subpopulation of the UK national population
 - ➔ Influenced by the same trends that impact national population
- Affluent, high income
 - ➔ Lower mortality rates, higher life expectancy, faster improvements
- Data very noisy
 - ➔ Changing contributors, changing numbers of lives and small numbers at high ages

■ Implications

- The socioeconomic fabric of the UK means that mortality rates and life expectancies should not diverge without bound over the long run
- This doesn't mean that they converge, rather they shouldn't get too far apart over the long run
- Noise may mask underlying relationships, particularly at high ages


Metric 1: Graduated mortality rates: Assured lives vs. national population

2005 mortality rates



Source: J.P. Morgan, LifeMetrics Index and CMI publications

Historical mortality rates age 65




Source: J.P. Morgan, LifeMetrics Index and CMI publications

At face value experience has been very different


Comparing graduated mortality rates 1961-2005

**Ratio of mortality rates
[assured / national]**



Source: J.P. Morgan, LifeMetrics Index and CMI publications

**Annualized improvements
1961-2005**




Source: J.P. Morgan, LifeMetrics Index and CMI publications

Assured population has lower mortality and higher improvements

Metric 2: Mortality improvements converge over the long run


Ratio of cumulative mortality improvements*: [assured / national]

Age group 50-59




Source: J.P. Morgan, LifeMetrics Index and CMI publications

Age group 60-69




Source: J.P. Morgan, LifeMetrics Index and CMI publications

Age group 70-79



Source: J.P. Morgan, LifeMetrics Index and CMI publications

Age group 80-89




Source: J.P. Morgan, LifeMetrics Index and CMI publications

* Ratio of annualized improvements since 1961


Aggregate correlations of changes in mortality rates

Aggregate correlation for individual ages



Source: J.P. Morgan, LifeMetrics Index and CMI publications

Aggregate correlation for 10-yr age buckets




Source: J.P. Morgan, LifeMetrics Index and CMI publications

- Aggregate correlations between assured lives and national population
 - Calculated as one correlation across time and age
 - Graduated mortality rates, non-overlapping time periods
- Correlations increase with the time horizon
 - But long horizons have few data points


Metric 3: Survival rates historically have differed, but increased broadly in unison

10-yr survival rates for age 65



Source: J.P. Morgan, LifeMetrics Index and CMI publications

Ratio of 10-yr survival rates




Source: J.P. Morgan, LifeMetrics Index and CMI publications

- Ratio of survival rates [assured / national]
 - Relatively constant through time
 - Increases with age
 - 1.03 (age 45); 1.19 (age 65); 1.36 (age 75); 1.55 (age 80)


Metric 4: Period life expectancy has increased broadly in step

Period life expectancy for age 65



Source: J.P. Morgan, LifeMetrics Index and CMI publications

Ratio of period life expectancy




Source: J.P. Morgan, LifeMetrics Index and CMI publications

- Ratio of life expectancy [assured / national]
 - Relatively constant through time
 - Increases with age
 - 1.14 (age 45); 1.22 (age 65); 1.24 (age 75); 1.24 (age 80)


45-year change in period life expectancy has been approximately the same for all ages

Increase of life expectancy 1961-2005 (years)



Source: J.P. Morgan, LifeMetrics Index and CMI publications

Increase of life expectancy 1961-2005 (%)




Source: J.P. Morgan, LifeMetrics Index and CMI publications

- Period life expectancy over 1961-2005
 - Similar percentage increases between the two populations
 - Greatest percentage increases for higher ages


Metric 5: Liability cash flows realized over 10-year historical periods

Cumulative 10-yr cash flow age 65



Source: J.P. Morgan, LifeMetrics Index and CMI publications

Ratio of 10-yr cash flow




Source: J.P. Morgan, LifeMetrics Index and CMI publications

- Lifetime annuity paying GBP1 annually to survivors of a cohort
 - Calculate sum of cash flows over 10 years
 - Ratio relatively constant through time
 - Ratio increases with age


Metric 6: Theoretical liability value: Fixed age perspective

Liability value for age 65



Source: J.P. Morgan, LifeMetrics Index and CMI publications

Ratio of liability values




Source: J.P. Morgan, LifeMetrics Index and CMI publications

- Lifetime annuity paying GBP1 annually to survivors of a cohort
 - Calculate theoretical annuity price, using mortality projection model
 - Ratio relatively constant through time
 - Ratio increases with age

Note: The calibration look-back period for mortality projection is 30 years and discount rate is assumed to be 5%


Theoretical liability value: Cohort perspective

Liability values for cohort aged 65 in 1991



Source: J.P. Morgan, LifeMetrics Index and CMI publications

Ratio of liability values for different cohorts in 1991



Source: J.P. Morgan, LifeMetrics Index and CMI publications

Note: The calibration period for mortality projection is 30 years and discount rate is assumed to be 5%

Agenda

	Page
Framework for longevity basis risk	2
Example from the UK	8
Example from the US	21
Drawing conclusions	31

California vs US national population: males

- California population is a affluent subset of the national population
 - Data collected by same process for both

- Characterized by:
 - Lower mortality rates
 - Higher mortality improvements
 - Higher life expectancy
 - Large subpopulation
 - Shorter history

US vs California population statistics


	National	California	%
Total (mm)	304.1	36.8	12%
Over 65 (mm)	38.9	4.1	11%
GDP per capita	\$37,899	\$42,064	111%

Source: U.S. Census Bureau and Bureau of Economic Analysis,
2008 figures

**Similar relationship to national population as in UK example, but
closer match in terms of size and profile**


Metric 1: Graduated mortality rates: California state population vs. US national population

2004 mortality rates



Source: J.P. Morgan, LifeMetrics Index, U.S. Census Bureau and CDC publications

Historical mortality rates age 65




Source: J.P. Morgan, LifeMetrics Index, U.S. Census Bureau and CDC publications

At face value experience looks comparable


Comparing graduated mortality rates 1980-2004

Ratio of mortality rates [assured / national]



Source: J.P. Morgan, LifeMetrics Index, U.S. Census Bureau and CDC publications

Annualized improvements 1980-2004




Source: J.P. Morgan, LifeMetrics Index, U.S. Census Bureau and CDC publications

California has lower mortality and higher improvements

Metric 2: Mortality improvements converge over the long run


Ratio of cumulative mortality improvements*: [California / national]

Age group 50-59




Source: J.P. Morgan, LifeMetrics Index, U.S. Census Bureau and CDC publications

Age group 60-69




Source: J.P. Morgan, LifeMetrics Index, U.S. Census Bureau and CDC publications

Age group 70-79



Source: J.P. Morgan, LifeMetrics Index, U.S. Census Bureau and CDC publications

Age group 80-89




Source: J.P. Morgan, LifeMetrics Index, U.S. Census Bureau and CDC publications

* Ratio of annualized improvements


Aggregate correlations of changes in mortality rates

Aggregate correlation for individual ages



Source: J.P. Morgan, LifeMetrics Index, U.S. Census Bureau and CDC publications

Aggregate correlation for 10-yr age buckets




Source: J.P. Morgan, LifeMetrics Index, U.S. Census Bureau and CDC publications

- Aggregate correlations between California and national population
 - Calculated as one correlation across time and age
 - Graduated mortality rates, non-overlapping time periods
- Correlations increase with the time horizon
 - But long horizons have few data points


Metric 3: Survival rates historically increased broadly in unison

10-yr survival rates for age 65



Source: J.P. Morgan, LifeMetrics Index, U.S. Census Bureau and CDC publications

Ratio of 10-yr survival rates




Source: J.P. Morgan, LifeMetrics Index, U.S. Census Bureau and CDC publications

- Ratio of survival rates [California / national]
 - Relatively constant through time
 - Increases with age
 - 1.00 (age 45); 1.04 (age 65); 1.07 (age 75); 1.09 (age 80)


Metric 4: Period life expectancy has increased broadly in step

Period life expectancy for age 65



Source: J.P. Morgan, LifeMetrics Index, U.S. Census Bureau and CDC publications

Ratio of period life expectancy




Source: J.P. Morgan, LifeMetrics Index, U.S. Census Bureau and CDC publications

- Ratio of life expectancy [California / US national]
 - Relatively constant through time
 - 1.03(age 45); 1.05 (age 65); 1.05 (age 75); 1.05 (age 80)


25-year change in period life expectancy has been approximately the same for all ages

Increase of life expectancy 1980-2004 (years)



Source: J.P. Morgan, LifeMetrics Index, U.S. Census Bureau and CDC publications

Increase of life expectancy 1980-2004 (%)




Source: J.P. Morgan, LifeMetrics Index, U.S. Census Bureau and CDC publications

- Period life expectancy over 1980-2004
 - Similar percentage increases between the two populations
 - Greatest percentage increases for higher ages


Metric 5: Liability cash flows realized over 10-year historical periods

Cumulative 10-yr cash flow age 65



Source: J.P. Morgan, LifeMetrics Index, U.S. Census Bureau and CDC publications

Ratio of 10-yr cash flow



Source: J.P. Morgan, LifeMetrics Index, U.S. Census Bureau and CDC publications

- Lifetime annuity paying \$1 annually to survivors of a cohort
 - Calculate sum of cash flows over 10 years
 - Ratio relatively constant through time
 - Ratio increases with age

Agenda

	Page
Framework for longevity basis risk	2
Example from the UK	8
Example from the US	21
Drawing conclusions	31

Conclusions from the US and UK examples

■ UK Assured Lives

- Smallish subgroup of national population
- Noise in data
- Age profile centered around people in their 40s, with few lives 65+
- Basis risk likely to be higher than for a large pension plan / annuity portfolio

■ California

- Large subgroup of national population
- Same process for data collection as national population, so less noise

■ Both


- Affluent subpopulations, with lower mortality and higher life expectancy than respective national populations
- Have larger numbers of lives and longer history than typical insurer annuity portfolios or pension plans

Implications for hedge effectiveness calculations:

Case study 1 – Retrospective effectiveness test (backtesting)

- **Case study:** Longevity hedge based on national population index
 - Hedge variability of cash flow
 - Retrospective hedge effectiveness test


Hedge effectiveness for an index hedge: Historical case study



Case Study2: Prospective hedge effectiveness test

- **Case study:** Longevity hedge based on national population index
 - Hedge variability of liability value
 - 94% correlation between 10-year improvements for pension plan and LifeMetrics hedge

Distribution of liability value in 10 years: Before and after hedging



Summary

■ Framework for basis risk analysis:

■ Focus on

- Data (metric, long horizon, analytical method)
- Context

■ Empirical analysis of UK and US case studies:

■ Significant evidence of stable relationships historically

- Correlations high when measured appropriately over long horizons
- Survivor rates, life expectancies, liability cash flows and value have moved proportionately over time
- Ratios are stable over the medium-to-long term

■ Risk reduction using national population longevity index-based hedges can be significant if hedge optimally calibrated